[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Propanc Biopharma Inc (PPCB)

Propanc Biopharma Inc (PPCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,899
  • Shares Outstanding, K 2,278
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,920 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 3.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +43.85%
on 06/10/26
6.79 -72.46%
on 06/11/26
+0.17 (+10.00%)
since 05/15/26
3-Month
1.30 +43.85%
on 06/10/26
6.79 -72.46%
on 06/11/26
-1.53 (-44.96%)
since 03/16/26
52-Week
1.30 +43.85%
on 06/10/26
270.25 -99.31%
on 08/01/25
-125.63 (-98.53%)
since 06/16/25

Most Recent Stories

More News
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations...

PPCB : 1.87 (-13.02%)
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting...

PPCB : 1.87 (-13.02%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 178.71 (+0.81%)
PPCB : 1.87 (-13.02%)
RHHBY : 51.1800 (+0.34%)
BMY : 55.92 (-0.57%)
$100 Million Deal Positions This Microcap at the Crossroads of Biotech and Digital Finance

The worlds of biotechnology and cryptocurrency are colliding in unprecedented ways. Once viewed as niche markets, digital assets are increasingly finding a role in corporate treasuries, offering liquidity,...

TSLA : 404.39 (-1.64%)
PPCB : 1.87 (-13.02%)
MRNA : 55.40 (+6.27%)
COIN : 169.18 (-0.26%)
Propanc Biopharma Enters Securities Purchase Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

PPCB : 1.87 (-13.02%)
From Lab Bench to Blockchain: How Biotech is Reinventing Funding

The %Biotech field is no stranger to scientific breakthroughs, but combining novel therapeutic platforms with progressive treasury strategies is relatively new, and potentially disruptive. Many companies,...

ETHZ : 3.53 (-7.59%)
^ETHUSD : 1,795.210 (-1.09%)
QNTM : 3.65 (-1.35%)
QNTM.CN : 5.0000 (-2.53%)
PPCB : 1.87 (-13.02%)
^ETHUSDT : 1,796.680 (-1.08%)
BTCS : 1.2050 (+0.42%)
^ETHBTC : 0.027310 (+0.02%)
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads

Innovation in %Biotech often comes from pushing both science and finance into new territory. As drug developers race toward clinical trials, two levers often distinguish those that succeed: strong intellectual...

MSTR : 122.77 (-6.38%)
BMNR : 16.21 (-5.26%)
^BTCUSDT : 65,869.32 (-0.98%)
PPCB : 1.87 (-13.02%)
HOTH : 1.3600 (+92.01%)
^BTCUSD : 65,785.48 (-1.03%)
Stopping Cancer Before It Spreads: The EMT Revolution in Oncology

Cancer's most insidious ability lies not just in its capacity to grow, but in its power to transform. When tumor cells undergo epithelial-to-mesenchymal transition (EMT), they shed their structured, anchored...

PPCB : 1.87 (-13.02%)
RHHBY : 51.1800 (+0.34%)
PFE : 26.04 (+0.15%)
BMY : 55.92 (-0.57%)
Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect

When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader...

SANA : 2.84 (-0.53%)
RHHVF : 404.1800 (-0.20%)
$SANA : 3,452.65 (+8.59%)
PPCB : 1.87 (-13.02%)
MRNA : 55.40 (+6.27%)
The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms

- Bristol Myers Squibb, Merck & Company, and GE Healthcare Technologies continue advancing the cancer care ecosystem through cutting-edge therapeutics and diagnostic innovations

NVDA : 207.41 (-2.37%)
MRK : 115.17 (+0.23%)
GEHC : 63.23 (-2.36%)
PPCB : 1.87 (-13.02%)
BMY : 55.92 (-0.57%)
BNTX : 89.54 (-1.39%)

Business Summary

Propanc Biopharma, Inc. is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company's products include PRP and PRP-DCM. Propanc Biopharma, Inc., formerly known as Propanc Health Group Corporation, is based...

See More

Key Turning Points

3rd Resistance Point 2.86
2nd Resistance Point 2.62
1st Resistance Point 2.39
Last Price 1.87
1st Support Level 1.92
2nd Support Level 1.68
3rd Support Level 1.45

See More

52-Week High 270.25
Fibonacci 61.8% 167.51
Fibonacci 50% 135.77
Fibonacci 38.2% 104.04
Last Price 1.87
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.